SBSandeep Banga

Sandeep Banga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandeep Banga has a total of 69 co-authors. Here are the top co-authors by number of shared publications:

  • Avani R. Patel

    Internal Medicine, Northern California Kaiser Permanente, Fremont, USA

    2 shared publications
  • Darrel C Gumm

    Division of Cardiology, University of Illinois College of Medicine at Peoria, OSF Saint Francis Medical Center, Peoria, IL, USA

    2 shared publications
  • George S. Abela

    Division of Cardiology, Michigan State University, East Lansing (G.S.A.).

    2 shared publications
  • Shantanu Singh

    Pulmonary Medicine, Marshall University School of Medicine, Huntington, USA

    2 shared publications
  • Sudhir Mungee

    Cardiology, University of Illinois College of Medicine, Order of St. Francis Medical Centre, Peoria, USA

    2 shared publications
  • Tinoy J Kizhakekuttu

    Cardiology, University of Illinois College of Medicine at Peoria, Order of St. Francis Medical Centre, Peoria, USA

    2 shared publications

Latest Publications

  • Open Access

    Transdermal bisoprolol for prevention of postoperative atrial fibrillation: A systematic review and meta‐analysis

    by Andrew G. Kim, Sandeep Banga, Qi Xuan Ang, Lalitsiri Atti, Harith Ghnaima, Saif AlAttal, Preeti Banga, Matthew D. Wilcox

    Background: The transdermal patch of bisoprolol available in Japan has been reported to demonstrate superior efficacy in preventing postoperative atrial fibrillation, possibly surpassing its oral counterpart. However, there has been no systematic review and meta‐analysis assessing the efficacy of transdermal bisoprolol.Methods: A comprehensive systematic literature search was conducted on PubMed, Embase, and Cochrane to identify all relevant studies assessing the efficacy of transdermal bisoprolol in preventing postoperative atrial fibrillation. The search covered studies from inception up to December 4, 2023. For data analysis, Review Manager (RevMan) 5.4 software was employed, using a random‐effects model to calculate risk ratios (RR) and 95% confidence intervals (CI).Results: Three studies, comprising a total of 551 patients (transdermal bisoprolol 228 and control 323), were included. There was a decreased risk of postoperative atrial fibrillation or atrial tachyarrhythmias in patients treated with transdermal bisoprolol (RR 0.43, 95% CI 0.27–0.67, p = .0002, I2 = 0%).Conclusion: Transdermal administration of bisoprolol has consistently shown efficacy, and this pooled analysis supports its effectiveness. The heterogeneity of the included studies limits certain interpretations. Future randomized clinical trials may elucidate the superiority of transdermal administration over oral administration.


  • Management of Atrial Fibrillation Post Transcatheter Aortic Valve Implantation

    by Sandeep Banga, George S. Abela, Frank Saltiel, Tim Fischell, Jagadeesh K. Kalavakunta, Abhinav Sood, George Jolly, Khalid Najib, Haya Al-Ali, Mohammed Qintar, et al.


  • Cardiac MRI as an Imaging Tool in Titin Variant-Related Dilated Cardiomyopathy

    by Sandeep Banga, Rhanderson Cardoso, Carson Castellani, Shaurya Srivastava, Jennifer Watkins, Joao Lima


  • Ventricular non-compaction review

    by Shaurya Srivastava, Majid Yavari, Abdullah Al-Abcha, Sandeep Banga, George Abela

    Left ventricular non-compaction cardiomyopathy (LVNC) is a rare and unclassified cardiomyopathy that carries the potential to cause heart failure, arrhythmias, and embolic events within adults. The diagnosis of this cardiomyopathy can be based off a variety of echocardiographic, cardiac magnetic resonance (CMR), and computed tomography (CT) imaging criteria; none of which have been standardized to establish a firm diagnosis. This is further complicated by the observation from prior studies that LVNC may present as different forms of cardiomyopathy, each with its own subset of nuances that may change treatment strategies. Management of such cardiomyopathy has been debated in terms of anticoagulation, electrophysiologic studies to prevent arrhythmia, as well as heart failure prevention. Not enough data exists in regard to establishing firm guidelines for management. The following article aims to provide a comprehensive review in regard to the etiologies, pathogenesis, diagnostic criteria, management, and treatment of LVNC.


  • Open Access

    CT assessment of the left atrial appendage post-transcatheter occlusion – A systematic review and meta analysis

    by Sandeep Banga, Mohammed Osman, Partho P. Sengupta, Mina M. Benjamin, Sirish Shrestha, Abhiram Challa, Irfan Zeb, Madhavi Kadiyala, James Mills, Sudarshan Balla, et al.


  • Persistent Right Venous Valve: Insights From Multimodality Imaging

    by Madhavi Kadiyala, Kevin Hui, Sandeep Banga, Rohit Seth Loomba, Natesa G. Pandian, Shelby Kutty

    Anatomic variants in the right atrium are under-recognized and under-reported phenomena in cardiac imaging. In the fetus, right atrium serves as a conduit for oxygenated blood to be delivered to the left heart bypassing the right ventricle and the nonfunctional lungs. The anatomy in the fetal right atrium is designed for such purposeful circulation. The right and left venous valves are prominent structures in the fetal heart that direct inferior vena caval flow towards the foramen ovale. These anatomic structures typically regress and the foramen ovale closes after birth. However, the venous valves can persist leading to a range of anatomic, physiological, and pathological consequences in the adult. We describe various presentations of persistent venous valves, focusing on the right venous valve in this illustrated multimodality imaging article.


  • Open Access

    Comparing sedation vs. general anaesthesia in transoesophageal echocardiography-guided percutaneous transcatheter mitral valve repair: a meta-analysis

    by Sandeep Banga, Abdul Moiz Hafiz, Youssef Chami, Darrel C Gumm, Preeti Banga, Carmen Howard, Minchul Kim, Partho P Sengupta

    Transoesophageal echocardiography-guided percutaneous transcatheter mitral valve repair (TOE-guided PMVR) using edge-to-edge leaflet plication is typically performed under general anaesthesia (GA). Increasing evidence supports the efficacy and safety of PMVR performed under conscious sedation (CS) or deep sedation (DS). We performed a meta-analysis comparing safety and efficacy of CS/DS vs. GA in PMVR. A comprehensive search was performed using PubMed, CINAHL, Ovid MEDLINE, Embase, and the Cochrane Library. Study characteristics, participant demographics, and procedural outcomes with both types of anaesthesia were analysed. Out of 73 articles, five met inclusion criteria. Overall, there was no significant difference in the primary outcome of procedural success rate [odds ratio (OR) 0.75; 95% confidence interval (CI) 0.30–1.88, I2= 0.0%, P = 0.538] or post-procedure in-hospital mortality (OR 1.02; 95% CI 0.38–2.71, I2= 0.0%, P = 0.970) in the patients undergoing PMVR under CS/DS vs. GA. The secondary endpoint of intensive care unit (ICU) length of stay (LOS) was significantly shorter in patients under CS/DS vs. GA (standardized mean difference, SMD = −0.97; 95% CI −1.75 to −0.20; P = 0.014), but the hospital LOS (SMD = 0.36; 95% CI −0.77 to 0.04, P = 0.078) did not show a statistically significant difference between the groups, although it was shorter in the CS/DS group. No difference was observed between CS/DS and GA in fluoroscopy time, procedure time, or complications, including pneumonia, stroke/transient ischaemic attack, and major bleeding. CS or DS has lower ICU LOS, but comparable procedural success rate and in-hospital mortality, making it a potential alternative to GA for TOE-guided PMVR.


  • Open Access

    The Patient Selection Criteria for Veno-arterial Extracorporeal Mechanical Oxygenation

    by Sandeep Banga, Abhiram Challa, Avani R. Patel, Shantanu Singh, Vamsi K. Emani

    Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) plays a crucial role in the management of patients with refractory cardiac and pulmonary dysfunction by providing temporary mechanical hemodynamic and respiratory support. However, the paucity of guidelines on indications for administering it and the failure to timely initiate VA-ECMO often result in a high in-hospital mortality rate and poor six-month outcomes after VA-ECMO deployment. Due to ethical issues, randomized controlled studies with VA-ECMO have not been conducted so that no recommended evidence-based guidelines exist for VA-ECMO patient-selection criteria. Therefore, the indication for administering the device depends solely on expert opinion after reviewing the literature. We conducted a review of the current literature to better understand and classify the need for proper patient selection, including proven indications for VA-ECMO.


  • Open Access

    Management of Resistant Hypertension Based on Recommendations from Different Guidelines and the Systolic Blood Pressure Intervention Trial

    by Sandeep Banga, Sudhir Mungee, Avani R Patel, Shantanu Singh, Tinoy J Kizhakekuttu

    The long-term management of patients with resistant hypertension has been made even more difficult by a "moving target" goal blood pressure (BP). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (INC 7) guidelines defined resistant hypertension as the failure to achieve goal BP in patients who are adhering to full doses of an appropriate three-drug regimen that includes a diuretic. The Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (INC 8) guidelines laid out more lenient target BP goals, without addressing the definition of resistant hypertension directly. The present scenario is a state of confusion, with providers selectively adopting recommendations from different guidelines. The Systolic Blood Pressure Intervention Trial (SPRINT) trial contributed to the confusion with further evidence supporting the strict control of hypertension. In addition, the failure of another trial on renal denervation in the US has essentially put an end to six long years of experimentation with catheter ablation in patients with resistant hypertension. Other therapies arc still experimental. Adding a new dimension of medical management, spironolactone has made a comeback in resistant hypertension, with reports of better responsiveness when added to existing anti-hypertensive therapy. The present review discusses the current state and management options for patients with resistant hypertension considering the new evidence. Newer advances in pharmacological and device therapy are also discussed to improve understanding and quality in the management of resistant hypertension.